Supernus (SUPN) PT Trimmed at Jefferies, But Survey Shows Significant Market Opportunity
Tweet Send to a Friend
Jefferies lowered its price target on Supernus Pharmaceuticals (NASDAQ: SUPN) from $13 to $9 but maintained a Buy rating after ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
